ABP 798

BIOLOGICAL2 trials

Sponsors

Amgen

Conditions

Arthritis, RheumatoidLymphoma, Non-Hodgkin

Phase 3

Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab

CompletedNCT02747043

AmgenLymphoma, Non-Hodgkin

Start: 2016-05-25End: 2019-06-28Updated: 2022-09-10

Study to Assess if ABP 798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis (RA) Compared to Rituximab

CompletedNCT02792699

AmgenArthritis, Rheumatoid

Start: 2016-05-17End: 2018-10-08Updated: 2020-10-06

Related Papers

Efficacy and Safety of ABP 798: Results from the JASMINE Trial in Patients with Follicular Lymphoma in Comparison with Rituximab Reference Product.

2020-10-0112 citations